years versus 1 year of adjuvant trastuzumab for HER 2-positive breast cancer ( HERA ) : an open-label , randomised controlled trial

@inproceedings{Goldhirsch2013yearsV1,
  title={years versus 1 year of adjuvant trastuzumab for HER 2-positive breast cancer ( HERA ) : an open-label , randomised controlled trial},
  author={Aron Goldhirsch and Richard D. Gelber and Marion Procter and Christian Jackisch and David Cameron and Harald A. Weber and Dominik Heinzmann and Eleanor T. Mcfadden and Mitch Dowsett and Michael Andersson and Ian Smith and Brian R. Leyland-Jones and Jos{\'e} Baselga},
  year={2013}
}
Aron Goldhirsch, Richard D Gelber, Martine J Piccart-Gebhart, Evandro de Azambuja, Marion Procter, Thomas M Suter, Christian Jackisch, David Cameron, Harald A Weber, Dominik Heinzmann, Lissandra Dal Lago, Eleanor McFadden, Mitch Dowsett, Michael Untch, Luca Gianni, Richard Bell, Claus-Henning Köhne, Anita Vindevoghel, Michael Andersson, A Murray Brunt, Douglas Otero-Reyes, Santai Song, Ian Smith, Brian Leyland-Jones*, Jose Baselga*, for the Herceptin Adjuvant (HERA) Trial Study Team 

Figures and Tables from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 77 CITATIONS, ESTIMATED 47% COVERAGE

Trastuzumab cardiotoxiciy: the age-old balance of risk and benefit

  • British Journal of Cancer
  • 2016
VIEW 1 EXCERPT
CITES RESULTS
HIGHLY INFLUENCED

Advances in HER2-Positive Breast Cancer: Novel Therapies and Adverse Event Management

Reshma Mahtani, Lisa Hineman
  • Journal of the advanced practitioner in oncology
  • 2019
VIEW 1 EXCERPT
CITES BACKGROUND

Breast cancer

Nadia Harbeck, Frédérique Penault-Llorca, +6 authors Fatima Cardoso
  • Nature Reviews Disease Primers
  • 2019

FILTER CITATIONS BY YEAR

2013
2019

CITATION STATISTICS

  • 1 Highly Influenced Citations

  • Averaged 10 Citations per year from 2017 through 2019

References

Publications referenced by this paper.
SHOWING 1-10 OF 16 REFERENCES

Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2010